

Unique clinico-biological, genetic and prognostic features of adult early T-cell precursor acute lymphoblastic leukemia

Eulàlia Genescà,^{1*} Mireia Morgades,² Pau Montesinos,³ Pere Barba,⁴ Cristina Gil,⁵ Ramon Guàrdia,⁶ María-José Moreno,⁷ Daniel Martínez-Carballeira,⁸ Irene García-Cadenas,⁹ Susana Vives,² Jordi Ribera,¹ José González-Campos,¹⁰ Celia González-Gil,¹ Lurdes Zamora,² José-Luís Ramírez,² Marina Díaz-Beya,¹¹ Santiago Mercadal,¹² María-Teresa Artola,¹³ Antònia Cladera,¹⁴ Mar Tormo,¹⁵ Arancha Bermúdez,¹⁶ Ferran Vall-Llovera,¹⁷ Pilar Martínez,¹⁸ María-Luz Amigo,¹⁹ Silvia Monsalvo,²⁰ Andrés Novo,²¹ Marta Cervera,²² Antoni García-Guiñón,²³ Jordi Juncà,² Juana Ciudad,²⁴ Alberto Orfao²⁴ and Josep-Maria Ribera^{1,2}

¹Josep Carreras Leukaemia Research Institute, Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona; ²Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona; ³Hospital Universitari i Politécnic La Fe & CIBERONC, Instituto Carlos III, Madrid; ⁴Clinical Hematology Service, Hospital Universitari de la Vall d'Hebron, Barcelona; ⁵Clinical Hematology Service, Hospital General de Alicante, Alicante; ⁶Clinical Hematology Service, Hospital Josep Trueta-ICO, Girona; ⁷Clinical Hematology Service, Hospital Virgen de la Victoria, Málaga; ⁸Clinical Hematology Service, Hospital Universitario Central de Asturias, Oviedo; ⁹Clinical Hematology Service, Hospital de la Santa Creu i Sant Pau, Barcelona; ¹⁰Clinical Hematology Service, Hospital Virgen del Rocío, Sevilla; ¹¹Clinical Hematology Service, Hospital Clínic de Barcelona, Barcelona; ¹²Clinical Hematology Service, Hospital Duran i Reynals-ICO, Hospitalet del Llobregat; ¹³Clinical Hematology Service, Hospital Universitario de Donostia, Donostia; ¹⁴Clinical Hematology Service, Hospital Son Llàtzer, Palma de Mallorca; ¹⁵Clinical Hematology Service, Hospital Clínico de Valencia, Valencia; ¹⁶Clinical Hematology Service, Hospital Marqués de Valdecilla, Santander; ¹⁷Clinical Hematology Service, Hospital Mútua de Terrassa, Terrassa; ¹⁸Clinical Hematology Service, Hospital 12 de Octubre, Madrid; ¹⁹Clinical Hematology Service, Hospital Morales Meseguer, Murcia; ²⁰Clinical Hematology Service, Hospital Gregorio Marañón, Madrid; ²¹Clinical Hematology Service, Hospital Son Espases, Palma de Mallorca; ²²Clinical Hematology Service, Hospital Joan XXIII, Tarragona; ²³Clinical Hematology Service, Hospital Arnau de Vilanova, Lleida and ²⁴Centro de Investigación del Cáncer (IBMCC-CSIC/USAL), Hospital Clínico Universitario de Salamanca, Instituto Bio-Sanitario de Salamanca, CIBERONC Salamanca, Spain

Correspondence:

EULALIA GENESCA' - egenesca@carrerasresearch.org

doi:10.3324/haematol.2019.225078

Supplemental Table 1. ETP-ALL multivariate analysis of prognostic factors for OS, EFS and CIR.

Independent prognostic factor	Hazard ratio (95%CI)	P-value
OS		
ETP-ALL	2.136 (1.29- 3.53)	0.003
WBC count	1.002 (1.000- 1.003)	0.02
EFS		
ETP-ALL	1.914 (1.178- 3.109)	0.009
WBC count	1.002 (1.000- 1.004)	0.02
CIR		
Age	0.979 (0.959- 0.999)	0.05

Age and WBC were considered as continuous variables

CI: confidence interval; OS: overall survival; EFS: event-free survival; CIR: cumulative incidence of relapse; WBC: white blood cell; ETP-ALL: early T-cell precursor acute lymphoblastic leukemia

Supplemental Figure 1. Outcome of adult ETP-ALL patients after allo-HSCT. (A) The Cumulative incidence of non-relapse related mortality (NRM) at 3-years of ETP-ALL patients was of 36% (95% CI: 12%- 61%) vs. 27% (95% CI: 9%- 48%) for the other non-ETP T-ALL cases. (B) The cumulative incidence of relapse (CIR) at 3-years was of 24% (95% CI: 5%-52%) for the ETP-ALL patients and 11% (95% CI: 2%-29%) for the non-ETP T-ALL cases.

